Completeness of the dataset (%) - stage complete by cancer site groups summary (persons)
Country average (population) | Country average (country) | England | Scotland | Northern Ireland | Wales | |
---|---|---|---|---|---|---|
All invasive xnmsc | 75.1% | 75.8% | 75.5% | 66.4% | 81.2% | 80.0% |
Haematology | 54.4% | 46.5% | 58.2% | 0.0% | 54.4% | 73.3% |
Head and Neck | 84.9% | 87.0% | 85.3% | 75.4% | 94.4% | 92.7% |
Lower GI | 84.2% | 83.7% | 85.1% | 68.5% | 89.7% | 91.4% |
Upper GI | 74.0% | 76.5% | 73.5% | 72.5% | 77.2% | 82.7% |
HPB | 68.4% | 70.9% | 68.2% | 66.4% | 76.9% | 72.1% |
Bronchus & Lung | 90.7% | 92.3% | 90.2% | 92.0% | 94.4% | 92.5% |
Melanoma | 85.5% | 80.5% | 88.0% | 54.5% | 86.4% | 93.3% |
Breast | 86.0% | 88.0% | 85.9% | 84.2% | 96.6% | 85.2% |
Cervix | 87.9% | 92.3% | 86.9% | 90.6% | 97.3% | 94.6% |
Other Female Genitals | 80.3% | 82.8% | 80.4% | 71.4% | 91.2% | 88.1% |
Prostate | 84.2% | 85.8% | 84.1% | 78.4% | 89.7% | 90.9% |
Bladder | 76.5% | 79.5% | 76.6% | 66.4% | 90.4% | 84.6% |
Kidney | 78.3% | 83.9% | 77.4% | 79.2% | 93.6% | 85.5% |
Thyroid and other endocrine glands | 65.8% | 70.4% | 64.8% | 70.4% | 74.3% | 71.9% |
Non Melanoma skin | 1.4% | 5.0% | 1.5% | 0.0% | 16.8% | 1.5% |
Brain | 0.6% | 0.3% | 0.7% | 0.0% | 0.0% | 0.7% |
CUP | 49.5% | 39.6% | 55.7% | 0.0% | 50.0% | 52.6% |
Other invasive cancer | 54.1% | 45.8% | 57.5% | 23.0% | 46.6% | 56.0% |